Smallpox

Morris & Dickson is the First U.S. Distributor for Bavarian Nordic’s JYNNEOS®, the Only FDA-approved Mpox Vaccine

Retrieved on: 
Wednesday, April 3, 2024
Infectious Diseases, Pharmaceutical, Health, Disease, Smallpox, Virus, Mpox, Viral disease, Infection, CDC, Bavarian Nordic, Family, FDA, Pharmaceutical industry

Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic’s newly launched mpox vaccine, JYNNEOS®.

Key Points: 
  • Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic’s newly launched mpox vaccine, JYNNEOS®.
  • As the only FDA-approved mpox vaccine, JYNNEOS is now commercially available in the U.S., marking a significant expansion for access.
  • Bavarian Nordic announced its commercial entry into the US on April 2, noting the ongoing need for the vaccine.
  • “We are proud to be a key partner in expanding access to this first-to-market vaccine,” says Layne Martin, head of Specialty at Morris & Dickson.

World Market for Vaccines 2024: From Smallpox to Polio - The Impact on Global Health - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Managed Care, General Health, Pharmaceutical, Medical Devices, Infectious Diseases, Hospitals, Clinical Trials, COVID-19, Biotechnology, Medical Supplies, FDA, Health, Tetanus, Molina Healthcare, Public, Vaccine, Rubella, Death, Diphtheria, Quality of life, Vaccine-preventable diseases, Disease, Smallpox, Vaccination, Measles

The World Market for Vaccines, 2024 offers the most up-to-date and comprehensive analysis of adult and pediatric preventative vaccines.

Key Points: 
  • The World Market for Vaccines, 2024 offers the most up-to-date and comprehensive analysis of adult and pediatric preventative vaccines.
  • Since the early 2000s, the publisher has consistently published new editions of The World Market for Vaccines every two years.
  • The report includes market forecasts, company market share data, and expert market estimates for different vaccine categories.
  • The World Market for Vaccines, 2024 also examines market trends for human vaccines used to prevent various diseases.

Biofactura, Inc. Expands presence at Riverside Tech Park in Frederick, Maryland to 17,520 Square Feet

Retrieved on: 
Wednesday, March 20, 2024
Baltimore/Washington International Airport, Quality control, Smallpox, History, National Cancer Institute, Investment, OED, Research, Statistics, NCI, Frederick Municipal Airport, Congestion, Biotechnology, George Washington University, NIH, Workforce, Economic development, Dulles International Airport, Development, Communication, Georgetown University, Cancer, University, Lease, Growth, Johns Hopkins University, Multimedia

FREDERICK, Md., March 20, 2024 /PRNewswire-PRWeb/ -- BioFactura, Inc. has signed a lease with St. John Properties, Inc. for 12,000 square feet of space at Riverside Tech Park, a 70-acre business community located in Frederick, Maryland. The biotechnology firm has occupied 5,520 square feet of space at 8435 Progress Drive in Riverside Technology Park since 2015 and this new requirement expands the company's presence to 17,520 square feet of space within the building. Danny Foit, Leasing Representative for St. John Properties represented the landlord.

Key Points: 
  • The biotechnology firm has occupied 5,520 square feet of space at 8435 Progress Drive in Riverside Technology Park since 2015 and this new requirement expands the company's presence to 17,520 square feet of space within the building.
  • "Riverside Tech Park is a well-designed and strategically-located business community," Dr. Hausfeld added.
  • BioFactura's product has the potential to prepare, augment current countermeasures and guard against a possible smallpox breakout on a global scale.
  • BioFactura relocated in 2015 with the initial 5,520 square foot facility at Riverside Tech Park.

NCLA Asks Supreme Court to Revisit 120-year-old Precedent that Led to Rights Abuses Amid Pandemic

Retrieved on: 
Monday, March 11, 2024
Court, COVID-19, Smallpox, FDA, MSU, Government, NCLA, Face, Policy, Public, Constitution, Science, Immunity, Supreme court, Failure, State government, Student, Vaccine

MSU fired two of NCLA’s three clients, all of whom had naturally acquired immunity to Covid, for refusing the vaccine.

Key Points: 
  • MSU fired two of NCLA’s three clients, all of whom had naturally acquired immunity to Covid, for refusing the vaccine.
  • NCLA further urges the Court to hold that MSU’s policy failed to meet that standard.
  • NCLA’s petition presents the Supreme Court with an ideal opportunity to correct this widespread misunderstanding before another emergency pandemic breaks out.
  • The Court needs to update the precedent to reflect current constitutional law.”
    “CDC’s flawed guidance was not subject to direct court challenge, because it was deemed mere guidance.

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024
Research, Smallpox, GeoVax, Matrix (biology), Neoplasm, Vaccine, Virus-like particle, ABL, COVID-19, Biotechnology, NIH, Hospital, Security (finance), Congress, Immunity, CGMP, DNA, Therapy, Pfizer, Acute leukemia, AACR, MUC-1, Conference, Vaccination, Safety, Chronic lymphocytic leukemia, Antigen, Patent, Clinical trial, Infection, MVA, SARS-CoV-2, Messenger, Cancer, CLL, Immunodeficiency, Risk, VP40, Death, Patient, HIV, Travel

ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.

Key Points: 
  • ET
    ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.
  • Results to date have demonstrated safety of this therapy and consistent reduction in treated tumors.
  • Cash Position: GeoVax reported cash balances of $6.5 million on December 31, 2023, as compared to $27.6 on December 31, 2022.
  • ET today, February 29, 2024, to review financial results and provide an update on corporate developments.

Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference

Retrieved on: 
Tuesday, February 20, 2024
Infection, Therapy, Fibromyalgia, TNX-102, Tonix Pharmaceuticals, Orphan drug, Smallpox, NIAID, Research, Annual report, NIH, CD40L, FDA, BIO, Prader–Willi syndrome, Sumatriptan, Government, Upsher-Smith Laboratories, Conference, Disease, Autoimmunity, University, COVID-19, PWS, Patient, Acute stress disorder, Security (finance), Long, Breakthrough therapy, Risk, IND, NDA, Failure, Long COVID, Cancer, Pharmaceutical industry

CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 26, 2024 at 1:30 p.m.

Key Points: 
  • CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 26, 2024 at 1:30 p.m.
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024.
  • A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024.

SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

Retrieved on: 
Monday, January 22, 2024
University, Biochemistry, Osteoarthritis, SIGA Technologies, Business administration, Pfizer, Infection, Inflammation, Drug development, TPOXX, Smallpox, Pain, Doctor of Philosophy, Pharmaceutical industry

SIGA’s current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024.

Key Points: 
  • SIGA’s current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024.
  • Additionally, she will represent SIGA in engagements with government partners in the U.S. and internationally, playing a pivotal role in securing new contracts and partnerships.
  • Prior to Xalud, Dr. Nguyen served as executive vice president of biopharma at PPD Inc., a leading global clinical research organization providing integrated drug development services.
  • She earned a Ph.D. in biochemistry and molecular genetics at the University of Virginia, as well as an M.B.A. from Darden Graduate School of Business Administration.

Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial

Retrieved on: 
Wednesday, January 3, 2024
Long COVID, Annual report, Hydrogen chloride, Upsher-Smith Laboratories, Long, Failure, Infection, Breakthrough therapy, NIAID, IND, Government, Research, FDA, Sumatriptan, Prader–Willi syndrome, NDA, Cancer, CD40L, Orphan drug, Risk, Disease, COVID-19, Fibromyalgia, Smallpox, Union, NIH, Patient, Therapy, Security (finance), Nature, PWS, Autoimmunity, Pharmaceutical industry

CHATHAM, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present and host investor meetings at the following January investor conferences:

Key Points: 
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • Tonix’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia.
  • Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of TNX-102 SL for the management of fibromyalgia in the second half of 2024.
  • TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA.

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Retrieved on: 
Tuesday, December 19, 2023
Mpox, HHS, Infection, Immune system, Biotechnology, NIAID, Virus, License, Vaccine, Patent, Disease, City, COH, GeoVax, COVID-19, Cancer, Smallpox, Bangladesh Technical Education Board, HIV, SARS-CoV-2, Orthopoxvirus, NIH, Immunization, MVA

The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.

Key Points: 
  • The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.
  • Modified Vaccinia Ankara (MVA) is the vaccine currently used and stockpiled in the U.S. Strategic National Stockpile for immunization against the Mpox and smallpox viruses.
  • The addition of the Mpox and smallpox indications to our NIAID License Agreement complements GeoVax’s license agreement with COH for GEO-CM04S1, which we also recently amended to obtain development and commercialization rights against orthopoxviruses in addition to SARS-CoV-2.
  • For those regions/populations where Mpox and/or smallpox may be of a concern, we believe our COVID-19 vaccine will be a better choice.”

Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting

Retrieved on: 
Monday, December 11, 2023
Long COVID, Hydrogen chloride, Long, Upsher-Smith Laboratories, Failure, National academy, Infection, Breakthrough therapy, NIAID, Binge eating disorder, Government, Research, Psychiatry, Sumatriptan, FDA, Pain, Prader–Willi syndrome, Cancer, CD40L, Orphan drug, Tonix Pharmaceuticals, Social anxiety disorder, Risk, COVID-19, Disease, Smallpox, CNS, Fibromyalgia, Obesity, Neurology, NIH, Central nervous system, Therapy, Security (finance), Annual report, Autoimmunity, Pharmaceutical industry

Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 - 2:45 p.m.

Key Points: 
  • Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 - 2:45 p.m.
  • A webcast of the meeting can be found here and will be available under the IR Events tab of the Tonix website at www.tonixpharma.com following the presentation.
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.